Oncolytics Biotech Inc. (ONCY) News

Oncolytics Biotech Inc. (ONCY): $1.02

0.01 (+0.99%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ONCY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#104 of 348

in industry

Filter ONCY News Items

ONCY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ONCY News Highlights

  • For ONCY, its 30 day story count is now at 3.
  • Over the past 28 days, the trend for ONCY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest ONCY News From Around the Web

Below are the latest news stories about ONCOLYTICS BIOTECH INC that investors may wish to consider to help them evaluate ONCY as an investment opportunity.

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of additional translational data from the AWARE-1 breast cancer window-of-opportunity study conducted in combination with SOLTI-Innovative Cancer Research at The San Antonio Breast Cancer Symposium (SABCS).

Yahoo | December 7, 2023

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab...

Yahoo | November 9, 2023

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Yahoo | November 9, 2023

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript November 3, 2023 Oncolytics Biotech Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07. Operator: Good morning, and welcome to Oncolytics Biotech’s Third Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the […]

Yahoo | November 5, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of a poster that provides further positive translational data from the previously completed AWARE-1 breast cancer window-of-opportunity study, sponsored by SOLTI-Innovative Cancer Research, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Yahoo | November 3, 2023

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Yahoo | November 3, 2023

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

Oncolytics Biotech® Inc. (NASDAQ: ONCY),( Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain.

Yahoo | October 23, 2023

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study

Oncolytics Biotech® Inc. (NASDAQ: ONCY), (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the poster presentation of interim results from the Phase 1/2 GOBLET study evaluating a combination treatment of pelareorep in patients with third-line (3L) metastatic colorectal cancer (CRC) regardless of microsatellite instability status at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain.

Yahoo | October 23, 2023

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2023.

Yahoo | October 20, 2023

Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the publication of two abstracts for posters to be presented during the upcoming European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20th to 24th at the IFEMA Madrid Conference Center in Madrid, Spain.

Yahoo | October 16, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!